详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [2]Hunan Canc Hosp, Changsha, Peoples R China [3]Shanghai Chest Hosp, Shanghai, Peoples R China [4]Union Hosp, Tongji Med Coll, Wuhan, Peoples R China [5]Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [6]China Med Univ, Shengjing Hosp, Shenyang, Peoples R China

出处：

ISSN：

关键词： SBRT GM-CSF pd-1 inhibitor

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2019]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 13.357 出版当年[2019版] 10.089 出版当年五年平均 12.46 出版前一年[2018版] 15.609 出版后一年[2020版]

第一作者：

第一作者单位： [1]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Sintilimab, SBRT and GM-CSF for metastatic NSCLC: A prospective, multicenter, phase II trial [2]Sintilimab, SBRT and GM-CSF for Metastatic NSCLC: A Prospective, Multicenter, Phase II Trial [3]PROSPECTIVE MULTICENTER RANDOMIZED TRIAL COMPARING ANTIFUNGAL EFFECT OF GM-CSF, G-CSF, OR COMBINATION OF GM-CSF AND G-CSF FOR NEUTROPENIC RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTATION [4]A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B [5]Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes. [6]GM-CSF在兔动脉粥硬化非梗死模型颅内血管生成中的作用及其机制的探讨 [7]Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation [8]Better approach for autoimmune pulmonary alveolar proteinosis treatment: inhaled or subcutaneous granulocyte-macrophage colony-stimulating factor: a meta-analyses [9]Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes (vol 13, 836958, 2022) [10]Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients